Abstract | INTRODUCTION: AREAS COVERED: This systematic review assesses investigational long-acting muscarinic antagonist in Phase I and II clinical trials over the last decade. It offers insights on whether LAMAs and/or their new formulations in clinical development can become effective treatments for COPD in the future. EXPERT OPINION: Research on LAMA seems to have come to a standstill, the few new molecules under study do not show distinctive characteristics compared to the previous ones. Muscarinic antagonist/β2-agonist (MABAs) appear to be the major innovation currently under investigation, and they could theoretically open new research frontiers on the effect between adrenergic and muscarinic interaction in the same cell.
|
Authors | Josuel Ora, Angelo Coppola, Mario Cazzola, Luigino Calzetta, Paola Rogliani |
Journal | Journal of experimental pharmacology
(J Exp Pharmacol)
Vol. 12
Pg. 559-574
( 2020)
ISSN: 1179-1454 [Print] New Zealand |
PMID | 33324119
(Publication Type: Journal Article, Review)
|
Copyright | © 2020 Ora et al. |